98530-12-2

Basic information

• Product Name: Interferon alfa-2b
• Synonyms: Interferon alfa-2b
• CAS NO: 98530-12-2
• Molecular Formula: C16H17Cl3I2N3NaO5S
• Molecular Weight: 746.54599
• Mol File: 98530-12-2.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Interferon alfa-2b(CAS DataBase Reference)
• NIST Chemistry Reference: Interferon alfa-2b(98530-12-2)
• EPA Substance Registry System: Interferon alfa-2b(98530-12-2)

Safety Data

• Hazardous Substances Data: 98530-12-2(Hazardous Substances Data)

Usage

Description

Interferon alfa-2b, also known as Intron A, is a water-soluble protein consisting of 165 amino acids with an approximate molecular mass of 19,200 Da. It is expressed from a recombinant strain of E. coli and has an arginine at position 23 and a histidine at position 34. This interferon molecule is a broad-spectrum agent with various therapeutic applications.
Used in Pharmaceutical Industry:
Interferon alfa-2b is used as a therapeutic agent for the treatment of various conditions, including hairy cell leukemia, condyloma acuminata (genital or venereal warts), AIDS-related Kaposi sarcoma, and chronic hepatitis B and C infections.
Used in Administration Methods:
Interferon alfa-2b can be administered by subcutaneous (SC), intramuscular (IM), or intravenous (IV) routes, either by infusion or by intralesional routes. The dosage ranges from 1 to 35 million IU/day, depending on the specific application.
Used in Drug Formulations:
The drug is supplied as a solution or as a powder for solution, and both forms contain albumin, glycine, and sodium phosphate buffer. It is important not to shake the vials, as this can affect the stability of the drug. Vials of solution should be stored at 2°C to 8°C without freezing, while the powder is stable for 18 months at room temperature or 7 days at 45°C.
Brand Names:
Intron A (Schering) and Intron A HSA-free (Schering) are the brand names under which Interferon alfa-2b is marketed.

Indications

Interferon alfa-2b (Intron A) is a recombinant DNA product derived from the interferon alfa-2b gene of human white blood cells. Its mechanism of antitumor action involves binding to a plasma membrane receptor but is otherwise poorly understood. Its serum half-life is 2 to 3 hours after parenteral administration.

Clinical Use

Interferon alfa-2b is useful in the treatment of a rare form of chronic leukemia, hairy cell leukemia, in which it produces remissions in 60 to 80% of patients. However, it has minimal antitumor activity in most human cancers.Remissions lasting a few months have been observed in 10 to 20% of patients with lymphomas, multiple myeloma, melanoma, renal cell carcinoma, and ovarian carcinoma.

Side effects

The adverse effects of interferon alfa-2b include fever and a flulike syndrome of muscle ache, fatigue, headache, anorexia, and nausea. Other less common side effects include leukopenia, diarrhea, dizziness, and skin rash.

Drug interactions

Potentially hazardous interactions with other drugs Aminophylline and theophylline: metabolism of aminophylline and theophylline reduced, consider reducing dose of aminophylline and theophylline. Antivirals: increased risk of peripheral neuropathy with telbivudine. Immunosuppressants, e.g. ciclosporin, tacrolimus, sirolimus may have an antagonistic effect. Administration of interferon in combination with other chemotherapeutic agents, e.g. cytarabine, cyclophosphamide, doxorubicin may lead to increased risk of severe toxicity.

Metabolism

Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.

InChI:InChI=1/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1